Bioverativ reports positive data from long-term study of Alprolix

Bioverativ and its partner Sobi have announced new clinical trial data supporting the long-term benefits of Alprolix in the treatment of haemophilia B.

Results from the B-YOND extension trial have demonstrated the safety and efficacy of the drug in previously-treated subjects with severe haemophilia B over an extended period of time. 

Data published in the medical journal Thrombosis and Haemostasis showed that prophylactic treatment with Alprolix over a median duration of more than three years resulted in zero patients developing inhibitors, the neutralising antibodies that can interfere with successful therapy.

B-YOND represents the longest-term study of an extended half-life therapy for haemophilia B conducted to date.

Dr Maha Radhakrishnan, senior vice-president of medical at Bioverativ, said: "These results confirm the long-term safety and efficacy profile of Alprolix and show that a majority of the participants in the study were able to dose once weekly or less frequently while maintaining adequate protection."

Bioverativ commenced life as a standalone company a month ago, having been spun out from Biogen to operate as a dedicated haemophilia-focused business.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.